Nirsevimab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Nirsevimab. Educational only — not medical advice.
Labeled uses
BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in: • Neonates and infants born during or entering their first RSV season. • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
Source: FDA labeling via NIH DailyMed (set 2f08fa60…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.